Phenotypic screening has the potential to discover novel therapeutic targets. Find out how Charles River has discovered 75 preclinical drug candidates over the past 17 years using small molecules in BioCompare.
The biosimilar industry is growing. Mario DiPaola, Sr. Scientific Director at Charles River, breaks down the imbalance in the industry and why we could see some major changes in Contract Pharma.
Charles River talks with BioCompare about the future of high-throughput screening (HTS) – outsourcing, innovative technologies, and more.
Drug Target Review editor Steve Bremer asks David F Fischer, Executive Director Biology at Charles River, for his views on target discovery and validation in drug discovery.
“Currently there isn’t a well-defined reimbursement framework for biosimilars. Unless this is addressed swiftly and correctly, it is likely to undermine the sustainability of this new market.” Read more from Mario DiPaola, Sr. Scientific Director at Charles River, in BioProcess International’s recent blog post.
Charles River Laboratories has beefed up its library of patient-derived xenografts (PDXs) by adding new molecular characteristics into the mix.
Grace Lee, Corporate Sr. VP of Global HR, talks about the benefits of working at Charles River in BioSpace.
Mario DiPaola, Sr. Scientific Director at Charles River, discusses antibody-drug conjugates with BioCompare.
Asia is emerging as the next hot market for research animals. Now nearly half of the global market for mouse models is dominated by China, Singapore, Malaysia, and India. Terry Fisher of Charles River discusses with Lab Animal magazine.
Biosimilars are poised to have an even bigger impact on both European and US markets, with MAbs representing the most attractive targets for developers of these follow-on products. Ulrike Herbrand of Charles River discusses in Bioprocess International.